Evidence for cyclic diguanylate as a vaccine adjuvant with novel immunostimulatory activities

被引:66
作者
Gray, Peter M. [1 ]
Forrest, Gail [1 ]
Wisniewski, Thomas [1 ]
Porter, Gene [1 ]
Freed, Daniel C. [1 ]
DeMartino, Julie A. [1 ]
Zaller, Dennis M. [1 ]
Guo, Zhiqiang [1 ]
Leone, Joseph [1 ]
Fu, Tong-Ming [1 ]
Vora, Kalpit A. [1 ]
机构
[1] Merck Sharp & Dohme Corp, Whitehouse Stn, NJ USA
关键词
Adjuvant; Th; 1; Intracellular; c-di-GMP; C-DI-GMP; T-CELL RESPONSES; DENDRITIC CELLS; INTERFERON-GAMMA; IMMUNE-RESPONSES; MUCOSAL IMMUNITY; ACTIVATION; MATURATION; INFECTION; RECEPTOR;
D O I
10.1016/j.cellimm.2012.07.006
中图分类号
Q2 [细胞生物学];
学科分类号
071013 [干细胞生物学];
摘要
Cyclic diguanylate (c-di-GMP), a bacterial signaling molecule, possesses protective immunostimulatory activity in bacterial challenge models. This study explored the potential of c-di-GMP as a vaccine adjuvant comparing it with LPS, CpG oligonucleotides, and a conventional aluminum salt based adjuvant. In this evaluation, c-di-GMP was a more potent activator of both humoral and Th1-like immune responses as evidenced by the robust IgG2a antibody response it induced in mice and the strong IFN-gamma. TNF-alpha and IP-10 responses, it elicited in mice and in vitro in non-human primate peripheral blood mononuclear cells. Further, compared to LPS or CpG, c-di-GMP demonstrated a more pronounced ability to induce germinal center formation, a hallmark of long-term memory, in immunized mice. Together, these data add to the growing body of evidence supporting the utility of c-di-GMP as an adjuvant in vaccination for sustained and robust immune responses and provide a rationale for further evaluation in appropriate models of immunization. (C) 2012 Elsevier Inc. All rights reserved.
引用
收藏
页码:113 / 119
页数:7
相关论文
共 45 条
[1]
New approach for the synthesis of c-di-GMP and its analogues [J].
Amiot, Nicolas ;
Heintz, Karine ;
Giese, Bernd .
SYNTHESIS-STUTTGART, 2006, (24) :4230-4236
[2]
Bode C, 2011, EXPERT REV VACCINES, V10, P499, DOI [10.1586/ERV.10.174, 10.1586/erv.10.174]
[3]
STING is a direct innate immune sensor of cyclic di-GMP [J].
Burdette, Dara L. ;
Monroe, Kathryn M. ;
Sotelo-Troha, Katia ;
Iwig, Jeff S. ;
Eckert, Barbara ;
Hyodo, Mamoru ;
Hayakawa, Yoshihiro ;
Vance, Russell E. .
NATURE, 2011, 478 (7370) :515-U111
[4]
Interferon-γ and interleukin-12 pathway defects and human disease [J].
Dorman, SE ;
Holland, SM .
CYTOKINE & GROWTH FACTOR REVIEWS, 2000, 11 (04) :321-333
[5]
The bacterial second messenger cyclic diGMP exhibits potent adjuvant properties [J].
Ebensen, Thomas ;
Schulze, Kai ;
Riese, Peggy ;
Link, Claudia ;
Morr, Michael ;
Guzman, Carlos A. .
VACCINE, 2007, 25 (08) :1464-1469
[6]
El Sahly H, 2010, EXPERT REV VACCINES, V9, P1135, DOI [10.1586/ERV.10.111, 10.1586/erv.10.111]
[7]
Garçon N, 2011, EXPERT REV VACCINES, V10, P471, DOI [10.1586/erv.11.29, 10.1586/ERV.11.29]
[8]
Deficient IL-12(p35) gene expression by dendritic cells derived from neonatal monocytes [J].
Goriely, S ;
Vincart, B ;
Stordeur, P ;
Vekemans, J ;
Willems, F ;
Goldman, M ;
De Wit, D .
JOURNAL OF IMMUNOLOGY, 2001, 166 (03) :2141-2146
[9]
A defect in nucleosome remodeling prevents IL-12(p35) gene transcription in neonatal dendritic cells [J].
Goriely, S ;
Van Lint, C ;
Dadkhah, R ;
Libin, M ;
De Wit, D ;
Demonté, D ;
Willems, F ;
Goldman, M .
JOURNAL OF EXPERIMENTAL MEDICINE, 2004, 199 (07) :1011-1016
[10]
c-di-GMP as a vaccine adjuvant enhances protection against systemic methicillin-resistant Staphylococcus aureus (MRSA) infection [J].
Hu, Dong-Liang ;
Narita, Kouji ;
Hyodo, Mamoru ;
Hayakawa, Yoshihiro ;
Nakane, Akio ;
Karaolis, David K. R. .
VACCINE, 2009, 27 (35) :4867-4873